Wang et al. demonstrated in a study of patients with breast cancer that the degradation of Gal-1 improved the drug sensitivity of breast cancer by reducing the expression of P-gp by inhibiting the Raf-1/AP-1 pathway[112]. The gene discussed is RAF1; the disease is breast carcinoma.